Stocks TelegraphStocks Telegraph
Stock Ideas

IOVA Financial Statements and Analysis

NASDAQ : IOVA

Iovance Biotherapeutics, Inc.

$6.01
0.2+3.44%
Open: 3:04 PM
57.74
BESG ScoreESG Rating

IOVA FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

IOVA Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
revenue58.554M31.106M715.00K482.00K469.00K
cost of revenue39.823M36.746M12.535M14.079M4.34M
gross profit18.731M-5.64M-11.82M-13.597M-3.871M
gross profit ratio0.32-0.181-16.531-28.21-8.254
research and development expenses68.245M62.084M79.783M87.47M87.526M
general and administrative expenses008.263M49.314M26.964M
selling and marketing expenses0017.856M-29.125M0
selling general and administrative expenses39.553M34.19M26.119M20.189M26.964M
other expenses-1.00K0000
operating expenses107.797M96.274M105.902M107.659M114.49M
cost and expenses147.62M133.02M118.437M121.738M118.83M
interest income4.005M3.355M3.338M3.118M3.358M
interest expense00000
depreciation and amortization010.864M9.907M9.714M9.875M
ebitda-89.066M-91.05M-107.815M-111.542M-118.361M
ebitda ratio-1.521-2.927-150.79-231.415-252.369
operating income-89.066M-101.914M-117.722M-121.256M-118.361M
operating income ratio-1.521-3.276-164.646-251.568-252.369
total other income expenses net4.005M3.355M3.338M3.118M3.358M
income before tax-85.061M-98.559M-114.384M-118.138M-115.003M
income before tax ratio-1.453-3.168-159.978-245.10-245.209
income tax expense-1.52M-1.458M-1.408M-1.759M-1.243M
net income-83.541M-97.101M-112.976M-116.379M-113.76M
net income ratio-1.427-3.122-158.008-241.45-242.559
eps-0.28-0.34-0.42-0.45-0.46
eps diluted-0.28-0.34-0.42-0.45-0.46
weighted average shs out303.269M284.817M266.22M255.951M245.817M
weighted average shs out dil303.269M284.817M266.22M255.951M245.817M
Graph

IOVA Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
cash and cash equivalents164.186M228.752M134.188M114.888M267.72M
short term investments233.302M183.864M222.007M164.979M93.654M
cash and short term investments397.488M412.616M356.195M279.867M361.374M
net receivables55.768M31.604M234.00K151.00K1.00
inventory38.578M27.854M17.617M10.372M9.195M
other current assets6.744M10.257M11.487M17.458M12.017M
total current assets498.578M482.257M385.533M307.848M382.586M
property plant equipment net179.263M180.083M183.305M176.545M179.407M
goodwill00000
intangible assets306.639M295.299M294.303M0223.61M
goodwill and intangible assets306.639M295.299M294.303M229.258M223.61M
long term investments06.356M6.43M66.43M66.43M
tax assets0000-66.43M
other non current assets6.635M327.00K259.00K270.00K66.712M
total non current assets492.537M482.065M484.297M472.503M469.729M
other assets00000
total assets991.115M964.322M869.83M780.351M852.315M
account payables31.686M20.416M25.70M33.123M19.274M
short term debt022.872M11.078M7.777M10.468M
tax payables00000
deferred revenue0001.000
other current liabilities86.37M50.351M46.436M69.406M61.213M
total current liabilities118.056M93.639M83.214M110.306M90.955M
long term debt67.389M70.246M73.291M1.00M68.009M
deferred revenue non current068.246M71.291M00
deferred tax liabilities non current32.215M31.897M33.301M17.347M18.343M
other non current liabilities00067.085M1.00M
total non current liabilities99.604M102.143M106.592M85.432M87.352M
other liabilities00000
capital lease obligations77.94M69.246M72.291M67.085M78.477M
total liabilities217.66M195.782M189.806M195.738M178.307M
preferred stock3.00K3.00K3.00K3.00K3.00K
common stock13.00K12.00K12.00K11.00K11.00K
retained earnings-2.306B-2.222B-2.125B-2.012B-1.896B
accumulated other comprehensive income loss16.242M526.00K116.00K2.526M-9.097M
other total stockholders equity3.063B2.99B2.805B2.594B2.579B
total stockholders equity773.455M768.54M680.024M584.613M674.008M
total equity773.455M768.54M680.024M584.613M674.008M
total liabilities and stockholders equity991.115M964.322M869.83M780.351M852.315M
minority interest00000
total investments233.302M190.22M228.437M231.409M93.654M
total debt78.94M81.682M84.369M75.862M78.477M
net debt-85.246M-147.07M-49.819M-39.026M-189.243M
Graph

IOVA Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
deferred income tax-1.521M-1.458M-1.408M-1.759M-1.243M
stock based compensation31.006M30.466M17.178M14.399M15.821M
change in working capital71.26M-38.711M-32.549M11.888M5.89M
accounts receivables-24.164M-31.37M-83.00K-149.00K33.00K
inventory-10.873M-8.859M-6.735M-923.00K354.00K
accounts payables14.436M-10.39M-5.815M11.423M-9.766M
other working capital8.008M11.908M-19.916M1.537M15.269M
other non cash items-78.333M100.324M47.194M-1.833M-666.00K
net cash provided by operating activities-58.973M-98.429M-122.279M-83.97M-84.083M
investments in property plant and equipment-2.288M-442.00K-4.171M-3.529M-3.577M
acquisitions net00-52.573M253.00K-3.377M
purchases of investments-156.513M-74.339M-141.762M-107.569M-93.01M
sales maturities of investments110.00M115.00M87.00M38.00M20.95M
other investing activites040.661M-54.762M00
net cash used for investing activites-48.801M40.219M-111.506M-72.845M-79.014M
debt repayment00000
common stock issued45.202M153.825M198.277M1.148M203.179M
common stock repurchased7.263M-1.00M-4.701M0-379.00K
dividends paid00000
other financing activites-10.511M-1.00M-4.701M-186.00K-379.00K
net cash used provided by financing activities41.954M152.825M193.576M962.00K202.80M
effect of forex changes on cash616.00K-125.00K-491.00K3.021M-1.993M
net change in cash-58.211M94.564M19.30M-152.832M37.71M
cash at end of period170.541M228.752M134.188M114.888M267.72M
cash at beginning of period228.752M134.188M114.888M267.72M230.01M
operating cashflow-58.973M-98.429M-122.279M-83.97M-84.083M
capital expenditure-2.288M-442.00K-4.171M-3.529M-3.577M
free cash flow-61.261M-98.871M-126.45M-87.499M-87.66M
Graph

Frequently Asked Questions

How did Iovance Biotherapeutics, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?

A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, IOVA generated $58.55M in revenue last quarter, while its costs came in at $39.82M.

Last quarter, how much Gross Profit did Iovance Biotherapeutics, Inc. report?

A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Iovance Biotherapeutics, Inc. reported a $18.73M Gross Profit for the quarter ended Sep 30, 2024.

Have IOVA's Total Operating Expenses and Operating Income been favorable recently?

Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. IOVA incurred $107.80M worth of Operating Expenses, while it generated -$89.07M worth of Operating Income.

How much Net Income has IOVA posted recently?

The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Iovance Biotherapeutics, Inc., the company generated -$83.54M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.

At the end of the last quarter, how much Cash and Equivalents did Iovance Biotherapeutics, Inc. have?

The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Iovance Biotherapeutics, Inc. as of the end of the last quarter was $164.19M.

What are IOVA's Total Net Receivables for the last quarter?

Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, IOVA had Total Net Receivables of $55.77M.

In terms of Total Assets and Current Assets, where did Iovance Biotherapeutics, Inc. stand at?

An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of IOVA were $498.58M, while the Total Assets stand at $991.12M.

As of the last quarter, how much Total Debt did Iovance Biotherapeutics, Inc. have?

The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of IOVA's debt was $78.94M at the end of the last quarter.

What were IOVA's Total Liabilities during the last reported quarter?

A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, IOVA reported total liabilities of $217.66M.

How much did IOVA's Working Capital change over the last quarter?

Working Capital Change for IOVA was $71.26M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.

IOVA generated how much cash from operating activities?

An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. IOVA generated -$58.97M of Cash from Operating Activities during its recently reported quarter.

What was IOVA's latest reported Net Change in Cash?

An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. IOVA reported a -$58.21M Net Change in Cash in the most recent quarter.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph